Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Xanthosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.60 |
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.60 |
| ▸ | ADORA2A known ✓ | P29274 | 3/20 | 0.60 |
| ▸ | ADORA2B known ✓ | P29275 | 2/20 | 0.60 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.58 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.58 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.58 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.58 |
| ▸ | GAPDH | P04406 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | STAT6 | P42226 | 1/20 | 0.58 |
| ▸ | PI4KA | P42356 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Xanthosine SCHEMBL11523732 | 0.99 | LMNA (0.65) | LMNATP53NT5EHIF1AADORA3 | |
| Xanthosine SCHEMBL6676995 | 0.99 | LMNA (0.65) | LMNATP53NT5EHIF1AADORA3 | |
| Xanthosine SCHEMBL8665102 | 0.99 | LMNA (0.65) | LMNATP53NT5EHIF1AADORA3 | |
| Xanthosine SCHEMBL188120 | 0.99 | LMNA (0.65) | LMNATP53NT5EHIF1AADORA3 | |
| SCHEMBL597083 | 0.88 | LMNA (0.63) | LMNATP53NT5EHIF1AADORA3 | |
| SCHEMBL1371021 | 0.88 | LMNA (0.63) | LMNATP53NT5EHIF1AADORA3 | |
| SCHEMBL6673147 | 0.88 | LMNA (0.63) | LMNATP53NT5EHIF1AADORA3 | |
| SCHEMBL597084 | 0.88 | LMNA (0.63) | LMNATP53NT5EHIF1AADORA3 | |
| SCHEMBL11811220 | 0.86 | LMNA (0.62) | LMNATP53NT5EHIF1AADORA3 | |
| SCHEMBL6295569 | 0.86 | LMNA (0.77) | LMNATP53NT5EHIF1AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0743574-B1 | Migration imaging members | XEROX CORP (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0743573-B1 | Method for obtaining image contrast migration imaging members | XEROX CORP (US) | 2000-09-06 | — | — | EP | claimed |
| EP-0673783-B1 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORP (US) | 2000-07-05 | — | — | EP | claimed |
| EP-0743574-A2 | Migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| EP-0743573-A2 | Method for obtaining image contrast migration imaging members | XEROX CORPORATION (US) | 1996-11-20 | — | — | EP | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| CN-117159529-B | Palmitoylation inhibitor and application of palmitoylase ZDHHC24 inhibitor in liver cancer | 中山大学附属第一医院 | 2024-06-11 | — | — | CN | disclosed |
| CN-117159529-A | Palmitoylation inhibitor and application of palmitoylase ZDHHC24 inhibitor in liver cancer | 中山大学附属第一医院 | 2023-12-05 | — | — | CN | disclosed |
| US-7307166-B1 | Oxpurine nucleosides and their congeners, and acyl, derivatives thereof, for improvement of hematopoiesis | WELLSTAT THERAPEUTICS CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-6846525-B2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | PRO-NEURON, INC. | 2004-11-25 | — | — | US | disclosed |
| US-20040202825-A1 | RECORDING SHEETS CONTAINING PURINE, PYRIMIDINE, BENZIMIDAZOLE, IMIDAZOLIDINE, URAZOLE, PYRAZOLE, TRIAZOLE, BENZOTRIAZOLE, TETRAZOLE, AND PYRAZINE COMPOUNDS | XEROX CORPORATION | 2004-10-14 | — | — | US | disclosed |
| WO-1996004923-A1 | METHODS FOR TREATING SEPSIS OR INFLAMMATORY DISEASES WITH OXYPURINE NUCLEOSIDES | PRO-NEURON, INC. (US) | 1996-02-22 | — | — | WO | disclosed |
| EP-0570519-A4 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO NEURON INC (US) | 1996-02-21 | — | — | EP | disclosed |
| EP-0673783-A2 | Recording sheets containing purine, pyrimidine, benzimidazole, imidazolidine, urazole, pyrazole, triazole, benzotriazole, tetrazole, and pyrazine compounds | XEROX CORPORATION (US) | 1995-09-27 | — | — | EP | disclosed |
| EP-0570519-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1993-11-24 | — | — | EP | disclosed |
| WO-1992013561-A1 | OXYPURINE NUCLEOSIDES AND THEIR CONGENERS, AND ACYL DERIVATIVES THEREOF, FOR IMPROVEMENT OF HEMATOPOIESIS | PRO-NEURON, INC. (US) | 1992-08-20 | — | — | WO | disclosed |
| CN-1031537-A | Polymorphic forms of xanthosine and methods of use thereof | GORDON PAUL (US) | 1989-03-08 | — | — | CN | disclosed |
| WO-1988008747-A1 | MICROENCAPSULATION | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1988-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235782-A1 | Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis | TPMT, NUDT1, ENTPD5 | ADORA3 83/4885ADORA1 109/4885ADORA2A 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.